Biotechs turning to health foundations for cash

In most cases, biotech firms turn to venture capital, public stock offerings and traditional financing to fund their medical research efforts. However, in Massachusetts at least, biotechs are turning to nonprofit foundations to fund some of their research. For example, this week Epix Pharmaceuticals received about $38 million from the Cystic Fibrosis Foundation to help it find new drugs to treat the condition, contingent on meeting some of the foundation's goals. In other examples, the Juvenile Diabetes Research Foundation gave some of a recent $25 million grant round to three Boston-area biotech firms. And the Muscular Dystrophy Association has given $8.5 million to for-profits, with plans to give $1 million more to another Boston-area research house. Overall, disease-related foundations invested about $75 million in the biotech industry last year, according to industry publication CenterWatch Monthly.

To learn more about this funding approach:
- read this article from The Boston Globe
-
read this FierceBiotech piece

Related Articles:
Epix Pharmaceuticals expands collaboration with Cystic Fibrosis Foundation Therapeutics. Release
Foundation invests millions to find MS drug leads. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.